Janux Therapeutics, Inc. reported $24M of revenue over the trailing twelve months, +5367% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $24M (to Q2 2026). Net income: −$103M, trailing twelve months to Q2 2026. Free cash flow: −$42M, trailing twelve months to Q2 2026. EPS: −$1.64, trailing twelve months to Q2 2026.

JANXJanux Therapeutics, Inc.

Healthcare

$18.51-18% 1Y

$18.51

$12.1852 weeks$34.74

JANX as reported

Janux Therapeutics, Inc. reported $24M of revenue over the trailing twelve months, +5367% on the year before. 8 reported series are charted on this page, each one as filed.

$24M

Revenue, trailing twelve months · to Q2 2026 · +5367% against the twelve months before

Net income: −$103M
Net income · −2.9% year on year · trailing twelve months to Q2 2026
Free cash flow: −$42M
Free cash flow · −31% year on year · trailing twelve months to Q2 2026
EPS: −$1.64
EPS · −8.4% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for JANX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$24M	+5367%	Q2 2026
Net income	−$103M	−2.9%	Q2 2026
EPS	−$1.64	−8.4%	Q2 2026
Operating margin	−2646%	n/a	Q3 2024 · 7 quarters behind
Net margin	−2029%	n/a	Q3 2024 · 7 quarters behind
ROE	−11%	n/a	Q2 2026
ROA	−11%	n/a	Q2 2026
Free cash flow	−$42M	−31%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.